Patients considering or currently taking Semaglutide should have an open dialogue with their healthcare provider about these potential adverse effects, how to monitor for them, and strategies for management should they arise
Semaglutide: widely available, multiple options Semaglutide has the broadest availability of the three
Naltrexone-bupropion (Mysimba), which acts on central appetite regulation pathways, is licensed for weight management in the UK and requires review after 16 weeks (with a 5% weight loss threshold)
After first use, store at 2-8C
The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), traditionally recognized for their metabolic functions, also appear to influence central reward processing (14-16, 19, 20)
Recent FDA actions against certain compounding pharmacies, including recalls from providers like ProRx , highlight why pharmacy quality matters